Hasil Pencarian - Aaron C. Tan

  • Menampilkan 1 - 13 hasil dari 13
Perbaiki Hasil
  1. 1
    Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)

    Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC) oleh Aaron C. Tan

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in <i>EGFR</i>-Mutated NSCLC

    Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in <i>EGFR</i>-Mutated NSCLC oleh Keigo Kobayashi, Aaron C. Tan

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Anti-Angiogenic Therapy in <i>ALK</i> Rearranged Non-Small Cell Lung Cancer (NSCLC)

    Anti-Angiogenic Therapy in <i>ALK</i> Rearranged Non-Small Cell Lung Cancer (NSCLC) oleh Aaron C. Tan, Nick Pavlakis

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers

    Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers oleh Aaron C. Tan, Malinda Itchins, Mustafa Khasraw

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases

    Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases oleh Aaron C. Tan, Aaron C. Tan, Drexell H. Boggs, Eudocia Q. Lee, Michelle M. Kim, Minesh P. Mehta, Mustafa Khasraw

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    New drug developments in metastatic gastric cancer

    New drug developments in metastatic gastric cancer oleh Aaron C. Tan, David L. Chan, Wasek Faisal, Nick Pavlakis

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct

    Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct oleh Shamin Li, Summer Zhuang, Antja Heit, Si-Lin Koo, Aaron C. Tan, I-Ting Chow, William W. Kwok, Iain Beehuat Tan, Daniel S.W. Tan, Yannick Simoni, Evan W. Newell

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

    Systematic review of combinations of targeted or immunotherapy in advanced solid tumors oleh Mustafa Khasraw, Susan M Chang, Amy B Heimberger, Michael Lim, John Simes, Solmaz Sahebjam, Michael Platten, Wolfgang Wick, David M Ashley, Patrick Y Wen, Aaron C Tan, Stephen J Bagley, Howard Colman, Evanthia Galanis, Alireza Mansouri, Simon Khagi, Minesh P Mehta, Vinay K Puduvalli, Scott J Antonia, Don Berry

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure

    Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels... oleh Stephanie P.L. Saw, MRCP, Gek San Tan, MSc, Wei Chong Tan, MRCP, Aaron C. Tan, PhD, Gillianne G.Y. Lai, MRCP, Darren W.T. Lim, MRCP, Ravindran Kanesvaran, MRCP, Wan Ling Tan, MRCP, Sze Huey Tan, PhD, Kiat Hon Lim, FRCPA, Anders J. Skanderup, PhD, Daniel S.W. Tan, PhD

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer oleh Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Yu-Ting Chou, Siraj M. Ali, D. Lucas Kerr, Victor R. Olivas, Jonathan Shue, Julia Rotow, Manasi K. Mayekar, Franziska Haderk, Nilanjana Chatterjee, Anatoly Urisman, Jia Chi Yeo, Anders J. Skanderup, Aaron C. Tan, Wai Leong Tam, Oscar Arrieta, Kazuyoshi Hosomichi, Akihiro Nishiyama, Seiji Yano, Yuriy Kirichok, Daniel S.W. Tan, Rafael Rosell, Ross A Okimoto, Trever G. Bivona

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma

    A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma oleh Tira J. Tan, W. X. Gladys Ang, Who-Whong Wang, Hui-Shan Chong, Sze Huey Tan, Rachael Cheong, John Whay-Kuang Chia, Nicholas L. Syn, Wai Ho Shuen, Rebecca Ba, Nivashini Kaliaperumal, Bijin Au, Richard Hopkins, Xinhua Li, Aaron C. Tan, Amanda O. L. Seet, John E. Connolly, Thaschawee Arkachaisri, Valerie Chew, Ahmad bin Mohamed Lajam, Dianyan Guo, Marvin Z. W. Chew, Martin Wasser, Pavanish Kumar, Salvatore Albani, Han Chong Toh

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

    Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005) oleh Jiyun Lee, MD, Aaron C. Tan, BSc, M.B.B.S., PhD, FRACP, Siqin Zhou, MSc Statistics, Shinkyo Yoon, MD, PhD, Siyang Liu, MD, PhD, Ken Masuda, MD, Hidetoshi Hayashi, MD, PhD, Ullas Batra, MD, DM, Dong-Wan Kim, MD, PhD, Yasushi Goto, MD, PhD, Sze Huey Tan, PhD, Yi-Long Wu, MD, Dae Ho Lee, MD, PhD, Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, Myung-Ju Ahn, MD, PhD

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

    A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC oleh Gillianne G.Y. Lai, MBBS, Jia Chi Yeo, PhD, Amit Jain, MBBS, PhD, Siqin Zhou, MSc, Mengyuan Pang, MSc, Jacob J.S. Alvarez, BSc, Ngak Leng Sim, BCS, Aaron C. Tan, MBBS, FRACP, PhD, Lisda Suteja, BSc, Tze Wei Lim, BSc, Yu Amanda Guo, PhD, Meixin Shen, PhD, Stephanie P.L. Saw, MBBS, Neha Rohatgi, BSc, Joe P.S. Yeong, MBBS, PhD, Angela Takano, MBBS, Kiat Hon Lim, MBBS, Apoorva Gogna, MBBS, Chow Wei Too, MBBS, Kun Da Zhuang, MBBS, Wan Ling Tan, MBBS, Ravindran Kanesvaran, MBBS, Quan Sing Ng, MBBS, Mei Kim Ang, MBBS, Tanujaa Rajasekaran, MBBS, Lanying Wang, MBBS, Chee Keong Toh, MBBS, Wan-Teck Lim, MBBS, Wai Leong Tam, PhD, Sze Huey Tan, PhD, Anders M.J. Skanderup, PhD, Eng-Huat Tan, MBBS, Daniel S.W. Tan, BSc, MBBS, MRCP, PhD

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: